PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth while AVXL stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-83.05%
Negative gross profit growth while AVXL is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
7.21%
EBIT growth below 50% of AVXL's 32.53%. Michael Burry would suspect deeper competitive or cost structure issues.
7.21%
Operating income growth under 50% of AVXL's 32.53%. Michael Burry would be concerned about deeper cost or sales issues.
7.01%
Net income growth under 50% of AVXL's 15.02%. Michael Burry would suspect the firm is falling well behind a key competitor.
8.82%
EPS growth at 50-75% of AVXL's 15.38%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
8.82%
Diluted EPS growth at 50-75% of AVXL's 15.38%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
0.91%
Share reduction more than 1.5x AVXL's 2.87%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.91%
Diluted share reduction more than 1.5x AVXL's 2.87%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
1.55%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
1.40%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AVXL stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.07%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
81.18%
5Y OCF/share CAGR above 1.5x AVXL's 0.71%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
13.88%
3Y OCF/share CAGR at 50-75% of AVXL's 27.17%. Martin Whitman would suspect weaker recent execution or product competitiveness.
98.43%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
78.58%
5Y net income/share CAGR above 1.5x AVXL's 33.64%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-7.39%
Negative 3Y CAGR while AVXL is 14.02%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
109.82%
Below 50% of AVXL's 1026.76%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
14.99%
Below 50% of AVXL's 344.39%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-59.15%
Negative 3Y equity/share growth while AVXL is at 129.37%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
19.47%
Positive BV/share change while AVXL is negative. John Neff sees a clear edge over a competitor losing equity.
-6.20%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.94%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
28.45%
SG&A growth well above AVXL's 0.67%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.